Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Gene Editing Tool Market

ID: MRFR/HC/24618-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026

Gene Editing Tool Market Size, Growth Research Report By Technology (CRISPR-Cas9, TALENs, ZFNs, RGENs, MegaTALs), By Application (Research and Development, Diagnostics, Therapeutics), By End User (Academic Institutions, Biotechnology Companies, Hospitals and Clinics), By Disease (Oncology, Genetic Disorders, Infectious Diseases) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Competitor Industry Analysis and Trends Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Gene Editing Tool Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Technology (USD Billion)
  49.     4.1.1 CRISPR-Cas9
  50.     4.1.2 TALENs
  51.     4.1.3 ZFNs
  52.     4.1.4 RGENs
  53.     4.1.5 MegaTALs
  54.   4.2 Healthcare, BY Application (USD Billion)
  55.     4.2.1 Research and Development
  56.     4.2.2 Diagnostics
  57.     4.2.3 Therapeutics
  58.   4.3 Healthcare, BY End User (USD Billion)
  59.     4.3.1 Academic Institutions
  60.     4.3.2 Biotechnology Companies
  61.     4.3.3 Hospitals and Clinics
  62.   4.4 Healthcare, BY Disease (USD Billion)
  63.     4.4.1 Oncology
  64.     4.4.2 Genetic Disorders
  65.     4.4.3 Infectious Diseases
  66.   4.5 Healthcare, BY Region (USD Billion)
  67.     4.5.1 North America
  68.       4.5.1.1 US
  69.       4.5.1.2 Canada
  70.     4.5.2 Europe
  71.       4.5.2.1 Germany
  72.       4.5.2.2 UK
  73.       4.5.2.3 France
  74.       4.5.2.4 Russia
  75.       4.5.2.5 Italy
  76.       4.5.2.6 Spain
  77.       4.5.2.7 Rest of Europe
  78.     4.5.3 APAC
  79.       4.5.3.1 China
  80.       4.5.3.2 India
  81.       4.5.3.3 Japan
  82.       4.5.3.4 South Korea
  83.       4.5.3.5 Malaysia
  84.       4.5.3.6 Thailand
  85.       4.5.3.7 Indonesia
  86.       4.5.3.8 Rest of APAC
  87.     4.5.4 South America
  88.       4.5.4.1 Brazil
  89.       4.5.4.2 Mexico
  90.       4.5.4.3 Argentina
  91.       4.5.4.4 Rest of South America
  92.     4.5.5 MEA
  93.       4.5.5.1 GCC Countries
  94.       4.5.5.2 South Africa
  95.       4.5.5.3 Rest of MEA
  96. 5 SECTION V: COMPETITIVE ANALYSIS
  97.   5.1 Competitive Landscape
  98.     5.1.1 Overview
  99.     5.1.2 Competitive Analysis
  100.     5.1.3 Market share Analysis
  101.     5.1.4 Major Growth Strategy in the Healthcare
  102.     5.1.5 Competitive Benchmarking
  103.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  104.     5.1.7 Key developments and growth strategies
  105.       5.1.7.1 New Product Launch/Service Deployment
  106.       5.1.7.2 Merger & Acquisitions
  107.       5.1.7.3 Joint Ventures
  108.     5.1.8 Major Players Financial Matrix
  109.       5.1.8.1 Sales and Operating Income
  110.       5.1.8.2 Major Players R&D Expenditure. 2023
  111.   5.2 Company Profiles
  112.     5.2.1 CRISPR Therapeutics (CH)
  113.       5.2.1.1 Financial Overview
  114.       5.2.1.2 Products Offered
  115.       5.2.1.3 Key Developments
  116.       5.2.1.4 SWOT Analysis
  117.       5.2.1.5 Key Strategies
  118.     5.2.2 Editas Medicine (US)
  119.       5.2.2.1 Financial Overview
  120.       5.2.2.2 Products Offered
  121.       5.2.2.3 Key Developments
  122.       5.2.2.4 SWOT Analysis
  123.       5.2.2.5 Key Strategies
  124.     5.2.3 Intellia Therapeutics (US)
  125.       5.2.3.1 Financial Overview
  126.       5.2.3.2 Products Offered
  127.       5.2.3.3 Key Developments
  128.       5.2.3.4 SWOT Analysis
  129.       5.2.3.5 Key Strategies
  130.     5.2.4 Regeneron Pharmaceuticals (US)
  131.       5.2.4.1 Financial Overview
  132.       5.2.4.2 Products Offered
  133.       5.2.4.3 Key Developments
  134.       5.2.4.4 SWOT Analysis
  135.       5.2.4.5 Key Strategies
  136.     5.2.5 Caribou Biosciences (US)
  137.       5.2.5.1 Financial Overview
  138.       5.2.5.2 Products Offered
  139.       5.2.5.3 Key Developments
  140.       5.2.5.4 SWOT Analysis
  141.       5.2.5.5 Key Strategies
  142.     5.2.6 Cellectis (FR)
  143.       5.2.6.1 Financial Overview
  144.       5.2.6.2 Products Offered
  145.       5.2.6.3 Key Developments
  146.       5.2.6.4 SWOT Analysis
  147.       5.2.6.5 Key Strategies
  148.     5.2.7 Precision BioSciences (US)
  149.       5.2.7.1 Financial Overview
  150.       5.2.7.2 Products Offered
  151.       5.2.7.3 Key Developments
  152.       5.2.7.4 SWOT Analysis
  153.       5.2.7.5 Key Strategies
  154.     5.2.8 Sangamo Therapeutics (US)
  155.       5.2.8.1 Financial Overview
  156.       5.2.8.2 Products Offered
  157.       5.2.8.3 Key Developments
  158.       5.2.8.4 SWOT Analysis
  159.       5.2.8.5 Key Strategies
  160.     5.2.9 Boehringer Ingelheim (DE)
  161.       5.2.9.1 Financial Overview
  162.       5.2.9.2 Products Offered
  163.       5.2.9.3 Key Developments
  164.       5.2.9.4 SWOT Analysis
  165.       5.2.9.5 Key Strategies
  166.   5.3 Appendix
  167.     5.3.1 References
  168.     5.3.2 Related Reports
  169. 6 LIST OF FIGURES
  170.   6.1 MARKET SYNOPSIS
  171.   6.2 NORTH AMERICA MARKET ANALYSIS
  172.   6.3 US MARKET ANALYSIS BY TECHNOLOGY
  173.   6.4 US MARKET ANALYSIS BY APPLICATION
  174.   6.5 US MARKET ANALYSIS BY END USER
  175.   6.6 US MARKET ANALYSIS BY DISEASE
  176.   6.7 CANADA MARKET ANALYSIS BY TECHNOLOGY
  177.   6.8 CANADA MARKET ANALYSIS BY APPLICATION
  178.   6.9 CANADA MARKET ANALYSIS BY END USER
  179.   6.10 CANADA MARKET ANALYSIS BY DISEASE
  180.   6.11 EUROPE MARKET ANALYSIS
  181.   6.12 GERMANY MARKET ANALYSIS BY TECHNOLOGY
  182.   6.13 GERMANY MARKET ANALYSIS BY APPLICATION
  183.   6.14 GERMANY MARKET ANALYSIS BY END USER
  184.   6.15 GERMANY MARKET ANALYSIS BY DISEASE
  185.   6.16 UK MARKET ANALYSIS BY TECHNOLOGY
  186.   6.17 UK MARKET ANALYSIS BY APPLICATION
  187.   6.18 UK MARKET ANALYSIS BY END USER
  188.   6.19 UK MARKET ANALYSIS BY DISEASE
  189.   6.20 FRANCE MARKET ANALYSIS BY TECHNOLOGY
  190.   6.21 FRANCE MARKET ANALYSIS BY APPLICATION
  191.   6.22 FRANCE MARKET ANALYSIS BY END USER
  192.   6.23 FRANCE MARKET ANALYSIS BY DISEASE
  193.   6.24 RUSSIA MARKET ANALYSIS BY TECHNOLOGY
  194.   6.25 RUSSIA MARKET ANALYSIS BY APPLICATION
  195.   6.26 RUSSIA MARKET ANALYSIS BY END USER
  196.   6.27 RUSSIA MARKET ANALYSIS BY DISEASE
  197.   6.28 ITALY MARKET ANALYSIS BY TECHNOLOGY
  198.   6.29 ITALY MARKET ANALYSIS BY APPLICATION
  199.   6.30 ITALY MARKET ANALYSIS BY END USER
  200.   6.31 ITALY MARKET ANALYSIS BY DISEASE
  201.   6.32 SPAIN MARKET ANALYSIS BY TECHNOLOGY
  202.   6.33 SPAIN MARKET ANALYSIS BY APPLICATION
  203.   6.34 SPAIN MARKET ANALYSIS BY END USER
  204.   6.35 SPAIN MARKET ANALYSIS BY DISEASE
  205.   6.36 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
  206.   6.37 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
  207.   6.38 REST OF EUROPE MARKET ANALYSIS BY END USER
  208.   6.39 REST OF EUROPE MARKET ANALYSIS BY DISEASE
  209.   6.40 APAC MARKET ANALYSIS
  210.   6.41 CHINA MARKET ANALYSIS BY TECHNOLOGY
  211.   6.42 CHINA MARKET ANALYSIS BY APPLICATION
  212.   6.43 CHINA MARKET ANALYSIS BY END USER
  213.   6.44 CHINA MARKET ANALYSIS BY DISEASE
  214.   6.45 INDIA MARKET ANALYSIS BY TECHNOLOGY
  215.   6.46 INDIA MARKET ANALYSIS BY APPLICATION
  216.   6.47 INDIA MARKET ANALYSIS BY END USER
  217.   6.48 INDIA MARKET ANALYSIS BY DISEASE
  218.   6.49 JAPAN MARKET ANALYSIS BY TECHNOLOGY
  219.   6.50 JAPAN MARKET ANALYSIS BY APPLICATION
  220.   6.51 JAPAN MARKET ANALYSIS BY END USER
  221.   6.52 JAPAN MARKET ANALYSIS BY DISEASE
  222.   6.53 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
  223.   6.54 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
  224.   6.55 SOUTH KOREA MARKET ANALYSIS BY END USER
  225.   6.56 SOUTH KOREA MARKET ANALYSIS BY DISEASE
  226.   6.57 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
  227.   6.58 MALAYSIA MARKET ANALYSIS BY APPLICATION
  228.   6.59 MALAYSIA MARKET ANALYSIS BY END USER
  229.   6.60 MALAYSIA MARKET ANALYSIS BY DISEASE
  230.   6.61 THAILAND MARKET ANALYSIS BY TECHNOLOGY
  231.   6.62 THAILAND MARKET ANALYSIS BY APPLICATION
  232.   6.63 THAILAND MARKET ANALYSIS BY END USER
  233.   6.64 THAILAND MARKET ANALYSIS BY DISEASE
  234.   6.65 INDONESIA MARKET ANALYSIS BY TECHNOLOGY
  235.   6.66 INDONESIA MARKET ANALYSIS BY APPLICATION
  236.   6.67 INDONESIA MARKET ANALYSIS BY END USER
  237.   6.68 INDONESIA MARKET ANALYSIS BY DISEASE
  238.   6.69 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
  239.   6.70 REST OF APAC MARKET ANALYSIS BY APPLICATION
  240.   6.71 REST OF APAC MARKET ANALYSIS BY END USER
  241.   6.72 REST OF APAC MARKET ANALYSIS BY DISEASE
  242.   6.73 SOUTH AMERICA MARKET ANALYSIS
  243.   6.74 BRAZIL MARKET ANALYSIS BY TECHNOLOGY
  244.   6.75 BRAZIL MARKET ANALYSIS BY APPLICATION
  245.   6.76 BRAZIL MARKET ANALYSIS BY END USER
  246.   6.77 BRAZIL MARKET ANALYSIS BY DISEASE
  247.   6.78 MEXICO MARKET ANALYSIS BY TECHNOLOGY
  248.   6.79 MEXICO MARKET ANALYSIS BY APPLICATION
  249.   6.80 MEXICO MARKET ANALYSIS BY END USER
  250.   6.81 MEXICO MARKET ANALYSIS BY DISEASE
  251.   6.82 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
  252.   6.83 ARGENTINA MARKET ANALYSIS BY APPLICATION
  253.   6.84 ARGENTINA MARKET ANALYSIS BY END USER
  254.   6.85 ARGENTINA MARKET ANALYSIS BY DISEASE
  255.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
  256.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
  257.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
  258.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE
  259.   6.90 MEA MARKET ANALYSIS
  260.   6.91 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
  261.   6.92 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
  262.   6.93 GCC COUNTRIES MARKET ANALYSIS BY END USER
  263.   6.94 GCC COUNTRIES MARKET ANALYSIS BY DISEASE
  264.   6.95 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
  265.   6.96 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
  266.   6.97 SOUTH AFRICA MARKET ANALYSIS BY END USER
  267.   6.98 SOUTH AFRICA MARKET ANALYSIS BY DISEASE
  268.   6.99 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
  269.   6.100 REST OF MEA MARKET ANALYSIS BY APPLICATION
  270.   6.101 REST OF MEA MARKET ANALYSIS BY END USER
  271.   6.102 REST OF MEA MARKET ANALYSIS BY DISEASE
  272.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  273.   6.104 RESEARCH PROCESS OF MRFR
  274.   6.105 DRO ANALYSIS OF HEALTHCARE
  275.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  276.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  277.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  278.   6.109 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
  279.   6.110 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
  280.   6.111 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  281.   6.112 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  282.   6.113 HEALTHCARE, BY END USER, 2024 (% SHARE)
  283.   6.114 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
  284.   6.115 HEALTHCARE, BY DISEASE, 2024 (% SHARE)
  285.   6.116 HEALTHCARE, BY DISEASE, 2024 TO 2035 (USD Billion)
  286.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  287. 7 LIST OF TABLES
  288.   7.1 LIST OF ASSUMPTIONS
  289.     7.1.1
  290.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  291.     7.2.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  292.     7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
  293.     7.2.3 BY END USER, 2025-2035 (USD Billion)
  294.     7.2.4 BY DISEASE, 2025-2035 (USD Billion)
  295.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  296.     7.3.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  297.     7.3.2 BY APPLICATION, 2025-2035 (USD Billion)
  298.     7.3.3 BY END USER, 2025-2035 (USD Billion)
  299.     7.3.4 BY DISEASE, 2025-2035 (USD Billion)
  300.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  301.     7.4.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  302.     7.4.2 BY APPLICATION, 2025-2035 (USD Billion)
  303.     7.4.3 BY END USER, 2025-2035 (USD Billion)
  304.     7.4.4 BY DISEASE, 2025-2035 (USD Billion)
  305.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  306.     7.5.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  307.     7.5.2 BY APPLICATION, 2025-2035 (USD Billion)
  308.     7.5.3 BY END USER, 2025-2035 (USD Billion)
  309.     7.5.4 BY DISEASE, 2025-2035 (USD Billion)
  310.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  311.     7.6.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  312.     7.6.2 BY APPLICATION, 2025-2035 (USD Billion)
  313.     7.6.3 BY END USER, 2025-2035 (USD Billion)
  314.     7.6.4 BY DISEASE, 2025-2035 (USD Billion)
  315.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  316.     7.7.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  317.     7.7.2 BY APPLICATION, 2025-2035 (USD Billion)
  318.     7.7.3 BY END USER, 2025-2035 (USD Billion)
  319.     7.7.4 BY DISEASE, 2025-2035 (USD Billion)
  320.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  321.     7.8.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  322.     7.8.2 BY APPLICATION, 2025-2035 (USD Billion)
  323.     7.8.3 BY END USER, 2025-2035 (USD Billion)
  324.     7.8.4 BY DISEASE, 2025-2035 (USD Billion)
  325.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  326.     7.9.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  327.     7.9.2 BY APPLICATION, 2025-2035 (USD Billion)
  328.     7.9.3 BY END USER, 2025-2035 (USD Billion)
  329.     7.9.4 BY DISEASE, 2025-2035 (USD Billion)
  330.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  331.     7.10.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  332.     7.10.2 BY APPLICATION, 2025-2035 (USD Billion)
  333.     7.10.3 BY END USER, 2025-2035 (USD Billion)
  334.     7.10.4 BY DISEASE, 2025-2035 (USD Billion)
  335.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  336.     7.11.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  337.     7.11.2 BY APPLICATION, 2025-2035 (USD Billion)
  338.     7.11.3 BY END USER, 2025-2035 (USD Billion)
  339.     7.11.4 BY DISEASE, 2025-2035 (USD Billion)
  340.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  341.     7.12.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  342.     7.12.2 BY APPLICATION, 2025-2035 (USD Billion)
  343.     7.12.3 BY END USER, 2025-2035 (USD Billion)
  344.     7.12.4 BY DISEASE, 2025-2035 (USD Billion)
  345.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  346.     7.13.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  347.     7.13.2 BY APPLICATION, 2025-2035 (USD Billion)
  348.     7.13.3 BY END USER, 2025-2035 (USD Billion)
  349.     7.13.4 BY DISEASE, 2025-2035 (USD Billion)
  350.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  351.     7.14.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  352.     7.14.2 BY APPLICATION, 2025-2035 (USD Billion)
  353.     7.14.3 BY END USER, 2025-2035 (USD Billion)
  354.     7.14.4 BY DISEASE, 2025-2035 (USD Billion)
  355.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  356.     7.15.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  357.     7.15.2 BY APPLICATION, 2025-2035 (USD Billion)
  358.     7.15.3 BY END USER, 2025-2035 (USD Billion)
  359.     7.15.4 BY DISEASE, 2025-2035 (USD Billion)
  360.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  361.     7.16.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  362.     7.16.2 BY APPLICATION, 2025-2035 (USD Billion)
  363.     7.16.3 BY END USER, 2025-2035 (USD Billion)
  364.     7.16.4 BY DISEASE, 2025-2035 (USD Billion)
  365.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  366.     7.17.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  367.     7.17.2 BY APPLICATION, 2025-2035 (USD Billion)
  368.     7.17.3 BY END USER, 2025-2035 (USD Billion)
  369.     7.17.4 BY DISEASE, 2025-2035 (USD Billion)
  370.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  371.     7.18.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  372.     7.18.2 BY APPLICATION, 2025-2035 (USD Billion)
  373.     7.18.3 BY END USER, 2025-2035 (USD Billion)
  374.     7.18.4 BY DISEASE, 2025-2035 (USD Billion)
  375.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  376.     7.19.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  377.     7.19.2 BY APPLICATION, 2025-2035 (USD Billion)
  378.     7.19.3 BY END USER, 2025-2035 (USD Billion)
  379.     7.19.4 BY DISEASE, 2025-2035 (USD Billion)
  380.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  381.     7.20.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  382.     7.20.2 BY APPLICATION, 2025-2035 (USD Billion)
  383.     7.20.3 BY END USER, 2025-2035 (USD Billion)
  384.     7.20.4 BY DISEASE, 2025-2035 (USD Billion)
  385.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  386.     7.21.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  387.     7.21.2 BY APPLICATION, 2025-2035 (USD Billion)
  388.     7.21.3 BY END USER, 2025-2035 (USD Billion)
  389.     7.21.4 BY DISEASE, 2025-2035 (USD Billion)
  390.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  391.     7.22.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  392.     7.22.2 BY APPLICATION, 2025-2035 (USD Billion)
  393.     7.22.3 BY END USER, 2025-2035 (USD Billion)
  394.     7.22.4 BY DISEASE, 2025-2035 (USD Billion)
  395.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  396.     7.23.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  397.     7.23.2 BY APPLICATION, 2025-2035 (USD Billion)
  398.     7.23.3 BY END USER, 2025-2035 (USD Billion)
  399.     7.23.4 BY DISEASE, 2025-2035 (USD Billion)
  400.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  401.     7.24.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  402.     7.24.2 BY APPLICATION, 2025-2035 (USD Billion)
  403.     7.24.3 BY END USER, 2025-2035 (USD Billion)
  404.     7.24.4 BY DISEASE, 2025-2035 (USD Billion)
  405.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  406.     7.25.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  407.     7.25.2 BY APPLICATION, 2025-2035 (USD Billion)
  408.     7.25.3 BY END USER, 2025-2035 (USD Billion)
  409.     7.25.4 BY DISEASE, 2025-2035 (USD Billion)
  410.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  411.     7.26.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  412.     7.26.2 BY APPLICATION, 2025-2035 (USD Billion)
  413.     7.26.3 BY END USER, 2025-2035 (USD Billion)
  414.     7.26.4 BY DISEASE, 2025-2035 (USD Billion)
  415.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  416.     7.27.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  417.     7.27.2 BY APPLICATION, 2025-2035 (USD Billion)
  418.     7.27.3 BY END USER, 2025-2035 (USD Billion)
  419.     7.27.4 BY DISEASE, 2025-2035 (USD Billion)
  420.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  421.     7.28.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  422.     7.28.2 BY APPLICATION, 2025-2035 (USD Billion)
  423.     7.28.3 BY END USER, 2025-2035 (USD Billion)
  424.     7.28.4 BY DISEASE, 2025-2035 (USD Billion)
  425.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  426.     7.29.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  427.     7.29.2 BY APPLICATION, 2025-2035 (USD Billion)
  428.     7.29.3 BY END USER, 2025-2035 (USD Billion)
  429.     7.29.4 BY DISEASE, 2025-2035 (USD Billion)
  430.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  431.     7.30.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
  432.     7.30.2 BY APPLICATION, 2025-2035 (USD Billion)
  433.     7.30.3 BY END USER, 2025-2035 (USD Billion)
  434.     7.30.4 BY DISEASE, 2025-2035 (USD Billion)
  435.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  436.     7.31.1
  437.   7.32 ACQUISITION/PARTNERSHIP
  438.     7.32.1

Healthcare Market Segmentation

Healthcare By Technology (USD Billion, 2025-2035)

  • CRISPR-Cas9
  • TALENs
  • ZFNs
  • RGENs
  • MegaTALs

Healthcare By Application (USD Billion, 2025-2035)

  • Research and Development
  • Diagnostics
  • Therapeutics

Healthcare By End User (USD Billion, 2025-2035)

  • Academic Institutions
  • Biotechnology Companies
  • Hospitals and Clinics

Healthcare By Disease (USD Billion, 2025-2035)

  • Oncology
  • Genetic Disorders
  • Infectious Diseases

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions